Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen and CA 125 Doubling Time in Relapsed Ovarian Cancer
NCT00305838Phase 2Unknown
- Sponsor
- Mount Vernon Cancer Centre
- Start
- Mar 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Mount Vernon Cancer Centre. Primary endpoints: Percentage of patients with a log linear rise in CA 125 levels, Consistency of the log linear part of the curve and 2 more. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00305838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305838.